 |
|
Risk of Breast Cancer With Oral Contraceptive Use in Women With a Family History of Breast Cancer
Dawn M. Grabrick, MPH;
Lynn C. Hartmann, MD;
James R. Cerhan, MD, PhD;
Robert A. Vierkant, MAS;
Terry M. Therneau, PhD;
Celine M. Vachon, PhD, MPH;
Janet E. Olson, PhD, MPH;
Fergus J. Couch, PhD;
Kristin E. Anderson, PhD, MPH;
V. Shane Pankratz, PhD;
Thomas A. Sellers, PhD, MPH
JAMA. 2000;284:1791-1798.
Context Oral contraceptive (OC) use is weakly associated with breast cancer risk in the general population, but the association among women with a familial predisposition to breast cancer is less clear.
Objective To determine whether the association between OC use and risk of breast cancer is influenced by family history of the disease.
Design and Setting Historical cohort study of 426 families of breast cancer probands diagnosed between 1944 and 1952 at the Tumor Clinic of the University of Minnesota Hospital. Follow-up data on families were collected by telephone interview between 1991 and 1996.
Participants A total of 394 sisters and daughters of the probands, 3002 granddaughters and nieces, and 2754 women who married into the families.
Main Outcome Measure Relative risk (RR) of breast cancer associated with history of OC use by relationship to proband.
Results After accounting for age and birth cohort, ever having used OCs was associated with significantly increased risk of breast cancer among sisters and daughters of the probands (RR, 3.3; 95% confidence interval [CI], 1.6-6.7), but not among granddaughters and nieces of the probands (RR, 1.2; 95% CI, 0.8-2.0) or among marry-ins (RR, 1.2; 95% CI, 0.8-1.9). Results were essentially unchanged after adjustment for parity, age at first birth, age at menarche, age at menopause, oophorectomy, smoking, and education. The elevated risk among women with a first-degree family history of breast cancer was most evident for OC use during or prior to 1975, when formulations were likely to contain higher dosages of estrogen and progestins (RR, 3.3; 95% CI, 1.5-7.2). A small number of breast cancer cases (n = 2) limited the statistical power to detect risk among women with a first-degree relative with breast cancer and OC use after 1975.
Conclusions These results suggest that women who have ever used earlier formulations of OCs and who also have a first-degree relative with breast cancer may be at particularly high risk for breast cancer. Further studies of women with a strong family history who have used more recent lower-dosage formulations of OCs are needed to determine how women with a familial predisposition to breast cancer should be advised regarding OC use today.
Author Affiliations: Departments of Health Sciences Research (Ms Grabrick, Mr Vierkant, and Drs Cerhan, Therneau, Vachon, Olson, Pankratz, and Sellers), Medical Oncology (Dr Hartmann), Laboratory Medicine and Pathology, Biochemistry, and Molecular Biology (Dr Couch), Mayo Clinic and Mayo Clinic Cancer Center, Rochester, Minn, and the Division of Epidemiology, University of Minnesota School of Public Health and University of Minnesota Cancer Center, Minneapolis (Dr Anderson).
RELATED ARTICLES
Oral Contraceptives and Breast Cancer: A Note of Caution for High-Risk Women
Wylie Burke
JAMA. 2000;284(14):1837-1838.
EXTRACT
| FULL TEXT
October 11, 2000
JAMA. 2000;284(14):1863-1864.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
BRCA1 and BRCA2 as ovarian cancer susceptibility genes
Sowter and Ashworth
Carcinogenesis 2005;26:1651-1656.
ABSTRACT
| FULL TEXT
Genetic Risk Assessment and BRCA Mutation Testing for Breast and Ovarian Cancer Susceptibility: Systematic Evidence Review for the U.S. Preventive Services Task Force
Nelson et al.
ANN INTERN MED 2005;143:362-379.
ABSTRACT
| FULL TEXT
BRCA1 in hormonal carcinogenesis: basic and clinical research
Rosen et al.
Endocr Relat Cancer 2005;12:533-548.
ABSTRACT
| FULL TEXT
Oral Contraceptive Use and Risk of Early-Onset Breast Cancer in Carriers and Noncarriers of BRCA1 and BRCA2 Mutations
Milne et al.
Cancer Epidemiol. Biomarkers Prev. 2005;14:350-356.
ABSTRACT
| FULL TEXT
Low-Dose Dietary Phytoestrogen Abrogates Tamoxifen-Associated Mammary Tumor Prevention
Liu et al.
Cancer Res. 2005;65:879-886.
ABSTRACT
| FULL TEXT
Prevention of Hormone-Related Cancers: Breast Cancer
Dunn et al.
JCO 2005;23:357-367.
ABSTRACT
| FULL TEXT
Relation of Contraceptive and Reproductive History to Ovarian Cancer Risk in Carriers and Noncarriers of BRCA1 Gene Mutations
McGuire et al.
Am J Epidemiol 2004;160:613-618.
ABSTRACT
| FULL TEXT
Oral Contraceptive Use and Breast Cancer Risk: Modification by NAD(P)H:Quinone Oxoreductase (NQO1) Genetic Polymorphisms
Fowke et al.
Cancer Epidemiol. Biomarkers Prev. 2004;13:1308-1315.
ABSTRACT
| FULL TEXT
Deciphering the Role of Genetic Testing for Cancer
JWatch Women's Health 2003;2003:3-3.
FULL TEXT
Combination Estrogen-Progestin Oral Contraceptives
Petitti
NEJM 2003;349:1443-1450.
FULL TEXT
Genetics and the Management of Women at High Risk for Breast Cancer
Mincey
The Oncologist 2003;8:466-473.
ABSTRACT
| FULL TEXT
Hormonal and Dietary Modulation of Mammary Carcinogenesis in Mouse Mammary Tumor Virus-c-erbB-2 Transgenic Mice
Yang et al.
Cancer Res. 2003;63:2425-2433.
ABSTRACT
| FULL TEXT
Predictors of the plasma ratio of 2-hydroxyestrone to 16{alpha}-hydroxyestrone among pre-menopausal, nulliparous women from four ethnic groups
Jernstrom et al.
Carcinogenesis 2003;24:991-1005.
ABSTRACT
| FULL TEXT
Prescribing Oral Contraceptives for Women Older Than 35 Years of Age
Seibert et al.
ANN INTERN MED 2003;138:54-64.
ABSTRACT
| FULL TEXT
Evidence-based management options for women at increased breast/ovarian cancer risk
Pichert et al.
Ann Oncol 2003;14:9-19.
ABSTRACT
| FULL TEXT
Oral Contraceptives and the Risk of Breast Cancer in BRCA1 and BRCA2 Mutation Carriers
Narod et al.
JNCI J Natl Cancer Inst 2002;94:1773-1779.
ABSTRACT
| FULL TEXT
Oral Contraceptives and the Risk of Breast Cancer
Marchbanks et al.
NEJM 2002;346:2025-2032.
ABSTRACT
| FULL TEXT
Parity, Oral Contraceptives, and the Risk of Ovarian Cancer among Carriers and Noncarriers of a BRCA1 or BRCA2 Mutation
Modan et al.
NEJM 2001;345:235-240.
ABSTRACT
| FULL TEXT
Breast Tumor Immunophenotype of BRCA1-Mutation Carriers Is Influenced by Age at Diagnosis
Vaziri et al.
Clin. Cancer Res. 2001;7:1937-1945.
ABSTRACT
| FULL TEXT
Hormone Replacement Therapy After Breast Cancer: A Systematic Review and Quantitative Assessment of Risk
Col et al.
JCO 2001;19:2357-2363.
ABSTRACT
| FULL TEXT
Retinoids for Ovarian Cancer Prevention: Laboratory Data Set the Stage for Thoughtful Clinical Trials
Veronesi and Decensi
JNCI J Natl Cancer Inst 2001;93:486-488.
FULL TEXT
Survivors of Breast Cancer
Potter et al.
NEJM 2001;344:309-310.
FULL TEXT
Oral Contraceptives and Risk of Breast Cancer in Women With a Family History of Breast Cancer
Kirkland et al.
JAMA 2001;285:39-40.
FULL TEXT
Breast Cancer in Women with a Family History: Does OC Use Increase Risk?
JWatch Women's Health 2000;2000:1-1.
FULL TEXT
Breast Cancer Risk, Oral Contraceptive Use, and Family History
JWatch General 2000;2000:2-2.
FULL TEXT
Oral Contraceptives and Breast Cancer: A Note of Caution for High-Risk Women
Burke
JAMA 2000;284:1837-1838.
FULL TEXT
|
